EUCTR2008-005985-30-NL进行中（未招募）不适用
Is augmentation of PORH by rosuvastatin adenosine-receptor mediated? - rosucaf2
Department of Pharmacology-Toxicology0 个研究点开始时间: 2008年9月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Healthy volunteers, 18-50 years of age
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of any cardiovascular disease
- •Hypertension (in supine position: systole >140 mmHg, diastole >90 mmHg)
- •Diabetes Mellitus (fasting glucose >7.0 mmol/L or random glucose >11.0 mmol/L)
- •Hyperlipidemia (fasting total cholesterol >5.5 mmol/L or random cholesterol >6.5 mmol/L)
- •Alanine amino transferase >90 U/L
- •Creatin kinase >440 U/L
- •Raised rabdomyolysis risk:
- •- GFR <80 ml/min
- •- overt clinical signs of hypothyroidism
- •- Myopathy in family history
- •- Alcohol abuse
- •Concomitant chronic use of medication
- •Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures.
研究者
相似试验
已完成
4 期
Is augmentation of PORH by rosuvastatin adenosine-receptor mediated?NL-OMON32791niversitair Medisch Centrum Sint Radboud8
已完成
4 期
Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?Cardiovascular DiseaseAtherosclerosisNCT00851175Radboud University Medical Center8
已完成
不适用
The Effect of Rosuvastatin on Adenosine MetabolismAdenosine MetabolismNCT00554138Radboud University Medical Center24
招募中
3 期
A clinical trial to investigate the efficiency of rosuvastatin in acute cardiomyopathy induced anthracyclineCardiomyopathyIRCT2016121213090N3Vice chancellor for research of Mazandaran University of Medical Sciences80
招募中
不适用
Evaluation of the effect of rosuvastatin on renoprotective effectType 2 diabetesJPRN-UMIN000021583Rosuvastatin-kidney study group40